Pivotal Life Sciences | Portfolio Company News

MapLight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007

August 24, 2023

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints for the Treatment of Inflammation and Pain Following Cataract Surgery

August 08, 2023

IO Biotech, Inc. Announces $75 Million Private Placement Financing

August 07, 2023

Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors

August 07, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Occulis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

Evommune raises $50M to fund clinical trials in skin diseases

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline

December 06, 2022

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

November 01, 2022

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated

October 24, 2022

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

October 18, 2022

Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology

October 17, 2022

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

September 26, 2022

Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win

August 08, 2022

1 2 3